Therefore, tumor-infiltrating lymphocytes and the expression of PD-L1 are being considered as biomarkers capable of screening NSCLC patients most likely to respond to checkpoint antibody therapy (Johnson et al., 2014). This evidence concerns the gene CD274 and non-small cell lung carcinoma.